Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data
- 13 June 2016
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Drug Discovery
- Vol. 11 (8), 753-758
- https://doi.org/10.1080/17460441.2016.1193148
Abstract
Introduction: Patient-reported outcomes (PROs) reflect how patients feel and function as conveyed directly by patients themselves, for example symptoms and physical functioning. PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience. Areas covered: In this review, the authors describe approaches commonly used to assess PROs in drug development programs, including how to select or develop outcomes and measures, implement these in trials, and analyze data. Barriers and facilitators for effectively including PROs in clinical trials are discussed, and strategies for making labeling claims based on PRO data are noted. Expert opinion: Early planning with PRO experts is recommended to assure a successful PRO strategy in a product development program. Outcomes that are meaningful to patients should be rationally identified early in a product development program based on qualitative work, literature search and/or assumed mechanism of action. Measures corresponding to those outcomes should be selected or developed, with demonstration of robust psychometric properties in a related patient population. Ideally, these measures will be tested prior to a pivotal trial to support the design and analysis in the pivotal trial. Selection of timing and mode of assessments should be specified a priori and justified. If a labeling claim is sought, a statistical plan should be pre-specified. Strategies to minimize and handle missing data in analyses should be planned up front.Keywords
This publication has 24 references indexed in Scilit:
- Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related SymptomsClinical Cancer Research, 2016
- Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion CohortEuropean Urology, 2014
- The symptom burden of cancer: Evidence for a core set of cancer‐related and treatment‐related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns studyCancer, 2013
- Harnessing Technology to Improve Clinical Trials: Study of Real-Time Informatics to Collect Data, Toxicities, Image Response Assessments, and Patient-Reported Outcomes in a Phase II Clinical TrialJournal of Clinical Oncology, 2013
- Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate CancerJournal of Clinical Oncology, 2012
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisThe New England Journal of Medicine, 2012
- Reliability of adverse symptom event reporting by cliniciansQuality of Life Research, 2011
- Health care providers underestimate symptom intensities of cancer patients: A multicenter European studyHealth and Quality of Life Outcomes, 2010
- Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical ApproachesJournal of Clinical Oncology, 2007
- How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30Journal of Clinical Oncology, 2004